If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu. The Media Team cannot respond to ...
If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.
Historic ceremony marks the beginning of a new era in cancer care, led by Dana-Farber in collaboration with Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute broke ground on the Lavine ...
Dr. Brittany Bychkovsky is a medical oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School. She is a graduate of Harvard Medical School. She completed ...
A rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer ...
RAS(ON) Inhibitor Daraxonrasib Shows Promising Results in Advanced Pancreatic Cancer Phase 1/2 Study
The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in a phase 1/2 first-in-human trial in patients with previously treated, RAS-mutant, metastatic pancreatic ...
Marijuana smoking found to raise levels of potentially harmful chemicals but to a lesser degree than tobacco smoking Exposure to a toxic chemical associated with heightened risk for cardiovascular ...
Unintentional weight loss is associated with an increase in the risk of a cancer diagnosis within the coming year, according to a study from Dana-Farber Cancer Institute. Compared with participants ...
Dana-Farber Cancer Institute investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial, a first-of-its-kind randomized trial of teclistamab, a BCMA-targeted bispecific ...
March 2021 Editor’s Note: For information about the COVID-19 vaccine for cancer patients. Defects linked to disruption of key protein involved in fetal development Finding will help guide development ...
The U.S. Food and Drug Administration (FDA) approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute ...
Following State and City Approvals, New Cancer Hospital and Clinical Collaboration Enters Next Phase
With the recent completion of a multi-agency, state and city regulatory process, the clinical collaboration among Dana-Farber Cancer Institute (Dana-Farber), Beth Israel Deaconess Medical Center ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results